VTX-002(Venn Therapeutics)

N/A

Report date: 2024/10/23 14:32:06

Base Information

Drug NameVTX-002(Venn Therapeutics)
Drug Alias NameVTX-002(Venn Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-integrin alpha V/beta 8Anti-TGF-β
Targetsintegrin alpha V/beta 8Transforming growth factor beta
Therapy Area/IndicationsInflammationPulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVenn Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesVenn Therapeutics LLC
Inactive CompaniesN/A
Active IndicationsInflammationPulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A